These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3479925)

  • 1. Stabilization of acetylcholine receptors at neuromuscular junctions: analysis by specific antibodies.
    Stanley EF; Drachman DB
    Ann N Y Acad Sci; 1987; 505():121-32. PubMed ID: 3479925
    [No Abstract]   [Full Text] [Related]  

  • 2. Myasthenia gravis: prototype of the antireceptor autoimmune diseases.
    Schönbeck S; Chrestel S; Hohlfeld R
    Int Rev Neurobiol; 1990; 32():175-200. PubMed ID: 1706686
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.
    Heinemann S; Merlie J; Lindstrom J
    Nature; 1978 Jul; 274(5666):65-8. PubMed ID: 661995
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.
    Stanley EF; Drachman DB
    Science; 1978 Jun; 200(4347):1285-7. PubMed ID: 663610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):383-7. PubMed ID: 6101172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K; Konishi T; Ohta M
    Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nature and Action of Antibodies in Myasthenia Gravis.
    Ruff RL; Lisak RP
    Neurol Clin; 2018 May; 36(2):275-291. PubMed ID: 29655450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors.
    Lennon VA; Lambert EH
    Nature; 1980 May; 285(5762):238-40. PubMed ID: 6154894
    [No Abstract]   [Full Text] [Related]  

  • 11. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.
    Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
    Exp Neurol; 2012 Oct; 237(2):286-95. PubMed ID: 22789393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional inhibition of acetylcholine receptors by antibodies in myasthenic sera.
    Hall ZW; Pizzighella S; Gu Y; Vicini S; Schuetze SM
    Ann N Y Acad Sci; 1987; 505():272-85. PubMed ID: 2446552
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis.
    de la Porte S; Ragueh F; Eymard B; Courbin P; Chapron J; Koenig J
    J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autoantibodies in myasthenia gravis].
    Motomura M; Narita Masuda T
    Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging shows loss of synaptic sites from neuromuscular junctions in a model of myasthenia gravis.
    Rich MM; Colman H; Lichtman JW
    Neurology; 1994 Nov; 44(11):2138-45. PubMed ID: 7969973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the autoimmune response to acetylcholine receptor impairs neuromuscular transmission in myasthenia gravis and its animal model.
    Lindstrom J
    Fed Proc; 1978 Dec; 37(14):2828-30. PubMed ID: 214352
    [No Abstract]   [Full Text] [Related]  

  • 19. The pathogenesis of myasthenia gravis.
    Fulpius BW
    Bull Schweiz Akad Med Wiss; 1978 Mar; 34(1-3):25-31. PubMed ID: 667413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):377-82. PubMed ID: 6101171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.